Pancreatic Cancer Research

ResearcherJiangnan UniversityNo recent work listed

Xiaowen Su

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2023: 3 papers

Papers 3

  1. The DEAD-box RNA helicase, DDX60, Suppresses immunotherapy and promotes malignant progression of pancreatic cancer. First author DOI 10.1016/j.bbrep.2023.101488↗
  2. miR-33a-3p regulates METTL3-mediated AREG stability and alters EMT to inhibit pancreatic cancer invasion and metastasis. Co-author DOI 10.1038/s41598-023-39506-7↗
  3. Linc00662 m6A promotes the progression and metastasis of pancreatic cancer by activating focal adhesion through the GTF2B-ITGA1-FAK pathway. Co-author PMID 37293163↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tiantian Lai · 3 shared papers, 2023 · strength 0.53
  2. Shuo Zhang · 2 shared papers, 2023 · strength 0.36
  3. Hao Hu · 2 shared papers, 2023 · strength 0.36
  4. Junjing Zhou · 2 shared papers, 2023 · strength 0.33
  5. Leisheng Wang · 1 shared paper, 2023 · strength 0.19
  6. Changyong Zhao · 1 shared paper, 2023 · strength 0.17
  7. Minfeng Liu · 1 shared paper, 2023 · strength 0.17
  8. Shuo Zhang · 1 shared paper, 2023 · strength 0.17
  9. Hao Hu · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.